Clinical Trial Search

Primary: Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)…

Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to 48 Weeks — -4.0; -3.1; -0.6 percent change

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 7.2; 9.5 percent improvement — p=0.2735

Primary: Number of Participants Alive at Time of Last Follow-up. — 376; 385; 271; 280 Participants

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 10.7; 4.5 percent improvement — p=0.0854

Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants

Primary: Percent Of Participants With Treatment-emergent Adverse Events — 82.9 percent of participants

Primary: Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment — 0.5; 0.5 units on a scale — p=0.9173

Primary: Percentage of Participants With Clinically Significant Hypoglycemia — 6.6; 35.5 percentage of participants

Primary: Hemoglobin A1c (HbA1c) at 12 Weeks — 6.87; 6.93 percentage of HbA1c

Primary: Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time — 67; 65; 67; 60 Participants

Primary: Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c) — -0.82; -0.29 percentage of HbA1c

Primary: Percentage of Patients With Successful Treatment — 86.8; 76.6 Percentage of Participants

Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 — 89.4; 98.0 percentage of participants

Primary: Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1) — 70.6; 72.5; 78.6 Percentage of participants — p==0.005